Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting – Biogen

  1. Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting  Biogen
  2. Biogen and Stoke Therapeutics Present Promising Zorevunersen Data for Dravet Syndrome at 2025 American Epilepsy Society Annual Meeting  Quiver Quantitative

Continue Reading